Abstract
It is now becoming clear that several papain-like cysteine cathepsins are involved in the pathophysiology of diseases such as osteoporosis, autoimmune disorders, and cancer. Therefore, the development of potent and selective cathepsin inhibitors is an attractive subject for medicinal chemists. New advances have been made for nitrile-based inhibitors, leading to the identification of the cathepsin K inhibitor odanacatib and other candidates with potential for therapeutic use. This review summarizes the development of peptidic and peptidomimetic compounds with an electrophilic nitrile ‘warhead’ as inhibitors of the cysteine cathepsins B, S, L, C, and K. Peptide nitriles have been shown to reversibly react with the active site cysteine under formation of a covalent thioimidate adduct. The structural optimization with respect to the positions P3, P2, P1, P1, and P2 resulted in the identification of potent and selective inhibitors of the corresponding cathepsins. The underlying structure-activity relationships are discussed herein.
Keywords: Cathepsin, covalent modifier, cysteine protease, lysosomotropic property, osteoporosis, peptide nitrile, peptidomimetic, protease inhibitor, thioimidate
Current Topics in Medicinal Chemistry
Title: Development of Nitrile-Based Peptidic Inhibitors of Cysteine Cathepsins
Volume: 10 Issue: 3
Author(s): Maxim Frizler, Marit Stirnberg, Mihiret Tekeste Sisay and Michael Gutschow
Affiliation:
Keywords: Cathepsin, covalent modifier, cysteine protease, lysosomotropic property, osteoporosis, peptide nitrile, peptidomimetic, protease inhibitor, thioimidate
Abstract: It is now becoming clear that several papain-like cysteine cathepsins are involved in the pathophysiology of diseases such as osteoporosis, autoimmune disorders, and cancer. Therefore, the development of potent and selective cathepsin inhibitors is an attractive subject for medicinal chemists. New advances have been made for nitrile-based inhibitors, leading to the identification of the cathepsin K inhibitor odanacatib and other candidates with potential for therapeutic use. This review summarizes the development of peptidic and peptidomimetic compounds with an electrophilic nitrile ‘warhead’ as inhibitors of the cysteine cathepsins B, S, L, C, and K. Peptide nitriles have been shown to reversibly react with the active site cysteine under formation of a covalent thioimidate adduct. The structural optimization with respect to the positions P3, P2, P1, P1, and P2 resulted in the identification of potent and selective inhibitors of the corresponding cathepsins. The underlying structure-activity relationships are discussed herein.
Export Options
About this article
Cite this article as:
Frizler Maxim, Stirnberg Marit, Sisay Tekeste Mihiret and Gutschow Michael, Development of Nitrile-Based Peptidic Inhibitors of Cysteine Cathepsins, Current Topics in Medicinal Chemistry 2010; 10 (3) . https://dx.doi.org/10.2174/156802610790725452
DOI https://dx.doi.org/10.2174/156802610790725452 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Medicinal Chemistry Advancement in Life-Threatening Diseases
The current issue will highlight concise reports that specify ground-breaking insights, including the novel discovery of drug targets and their action mechanism or drugs of novel classes. These are projected to encourage medicinal chemistry future efforts to address the most challenging medical needs. The current issue highlights further efforts to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
High Throughput Screening Methodologies Classified for Major Drug Target Classes According to Target Signaling Pathways
Combinatorial Chemistry & High Throughput Screening Lifelong Endocrine Fluctuations and Related Cognitive Disorders
Current Pharmaceutical Design Recent Development in Neuronal Migration Disorders: Clinical, Neuroradiologic and Genetics Aspects
Current Pediatric Reviews Drug-Resistance in Central Nervous System Tumors: From the Traditional Cell-Resistance Model to the Genetically Driven Approaches on Therapy
Current Pharmaceutical Biotechnology Longitudinal Melatonin Production in Female Laboratory Rats During 1997-2006: Possible Modulatory Effects of Changing Solar Activity
Current Aging Science Possible Physiopathological Effects of the Transglutaminase Activity on the Molecular Mechanisms Responsible for Human Neurodegenerative Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Editorial [Hot Topic: Therapeutic Potential of Peptide Motifs - Part I (Executive Editor: Jean-Claude Herve)]
Current Pharmaceutical Design Physiological Roles of Neuronal Nicotinic Receptors Subtypes: New Insights on the Nicotinic Modulation of Neurotransmitter Release, Synaptic Transmission and Plasticity
Current Topics in Medicinal Chemistry Effect of Drugs in Cells and Tissues by NMR Spectroscopy
Current Topics in Medicinal Chemistry Neuromodulators and Therapeutic Targets in Neuropathic Pain: From Molecules to Man
CNS & Neurological Disorders - Drug Targets T-type Calcium Channels in Health and Disease
Current Medicinal Chemistry Synthesis and Anticonvulsant Activity of Some Novel 2-Methyl Imidazole Derivatives
Letters in Drug Design & Discovery Somatostatin sst4 Ligands: Chemistry and Pharmacology
Mini-Reviews in Medicinal Chemistry Brain Excitatory/Inhibitory Circuits Cross-Talking with Chromogranin A During Hypertensive and Hibernating States
Current Medicinal Chemistry Biochemical, Enzymatic and Molecular Properties of Renin/Prorenin Mediated by (Pro)Renin Receptor
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) An Update on GABA Analogs for CNS Drug Discovery
Recent Patents on CNS Drug Discovery (Discontinued) Structure-Activity Relationships for Serotonin Transporter and Dopamine Receptor Selectivity
Medicinal Chemistry Potential Therapeutic Role of Carnitine and Acetylcarnitine in Neurological Disorders
Current Pharmaceutical Design Investigation of the Roles of New Antiepileptic Drugs and Serum BDNF Levels in Efficacy and Safety Monitoring and Quality of Life: A Clinical Research
Current Clinical Pharmacology TMS - A New Neuroimaging Combinational Tool to Study Brain Function
Current Medical Imaging